

Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Wednesday 30 May 2018, 10:00 – 15:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:	1. Chair Professor Stephen O'Brien	Present for all notes
	2. Dr Alex Cale	Present for all notes
	3. Mr Michael Chambers	Present for all notes
	4. Dr David Chandler	Present for all notes
	5. Ms Gail Coster	Present for all notes
	6. Dr Prithwiraj Das	Present for all notes
	7. Dr Natalie Hallas	Present for all notes
	8. Mr John Hampson	Present for all notes
	9. Dr Nigel Langford	Present for all notes
	10. Dr Rubin Minhas	Present for all notes
	11. Dr Richard Nicholas	Present for all notes
	12. Prof Andrew Renehan	Present for all notes
	13. Dr Peter Selby	Present for all notes
	14. Dr Paul Tappenden	Present for all notes
	15. Dr Derek Ward	Present for all notes
	16. Dr Judith Wardle	Present for all notes

In attendance:

Helen Knight	Acting Programme Director, National Institute for Health and Care Excellence	Present for all notes
Frances Sutcliffe	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Stephanie Callaghan	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Gemma Barnacle	Project Manager, National Institute for	Present for all notes

Health and Care Excellence

Ismahan Abdullah	Administrator, National Institute for Health and Care Excellence	Present for all notes
Abi Senthinathan	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
Alexandra Filby	Technical Advisor, National Institute for Health and Care Excellence	Present for all notes

Non-public attendees:

Peter Cain	ERG representative	Present for notes 5 to 12
Steve Edwards	ERG representative	Present for notes 5 to 12
Kayleigh Kew	ERG representative	Present for notes 5 to 12
Charles Gore	Patient Expert	Present for notes 5 to 12
Syed Hyder Hussaini	Clinical Expert	Present for notes 5 to 12
Tim Meyer	Clinical Expert	Present for notes 5 to 12
Farouk Fernandes	Company representative	Present for notes 5 to 12
Cyndy Simon	Company representative	Present for notes 5 to 12
Lesley Hayes	NICE observer	Present for all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma [ID1089]
2. The Chair informed the Committee of the non-public observers at this meeting: Lesley Hayes
3. Apologies were received from Mr Kamal Balakrishnan, Prof Andrew Manca, Prof Matt Stevenson and Prof Robert Walton.

Any other Business

4. Ross Dent answered questions from the committee about the technical report stage and gathered feedback

Appraisal of lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma [ID1089]

Part 1 – Open session

5. The Chair welcomed the invited experts: Charles Gore, Syed Hyder Hussaini, Tim Meyer, Peter Cain, Steve Edwards and Kayleigh Kew to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Eisai to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
 - 7.1. Dr Alex Cale, Mr Michael Chambers, Mr David Chandler, Ms Gail Coster, Dr Prithwiraj Das, Dr Natalie Hallas, Mr John Hampson, Dr Nigel Langford, Dr Rubin Minhas, Dr Richard Nicholas, Prof Andrew Renehan, Dr Peter Selby, Dr Paul Tappenden, Dr Derek Ward and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma.
8. The Chair asked all NICE Staff to declare any relevant interests.
 - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma.
9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 9.1. Peter Cain, Steve Edwards, Kayleigh Kew, Charles Gore and Syed Hyder Hussaini declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma.
 - 9.2. Tim Meyer declared a personal non-specific financial interest as he has participated in an advisory board for the company who market this technology.
 - 9.2.1. It was agreed that this declaration would not prevent Tim Meyer from participating in this section of the meeting
10. The Chair introduced the lead team, Mr David Chandler, Ms Gail Coster and Dr Natalie Hallas who gave presentations on the clinical effectiveness and cost

effectiveness of lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

13. Discussion on confidential information continued. This information was supplied by the company.
14. The Committee continued to discuss the clinical and cost effectiveness of lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma.
 - 14.1. The committee decision was based on consensus.
15. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD)

Date, time and venue of the next meeting

16. Wednesday 27 June 2018, 10:00 – 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.